… Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm … of Imatinib initially as
salvage therapy in 2001 and subsequently as front line therapy revolutionized CML therapy, …

… Imatinib, the first BCR/ABL kinase inhibitor approved for the treatment of chronic myeloid
leukemia (CML), has changed the long-term outcome of patients affected by this disease. The …

… , S.; Iacobucci, I.; De Vivo, A.; Testoni, N.; Castagnetti, F.; Gugliotta, G.; et al. Effects and
outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid …

… The first trial with imatinib, a phase I study with poor risk CML patients, started in 1998. The
stunning results convinced even skeptics that further studies were indicated. In 1999, a group …

… ago, imatinib entered into … chronic myeloid leukemia (CML) became comparable to that of
aged-matched healthy subjects. The aims of treatment with tyrosine kinase inhibitors (TKIs) are …

… Real-world evidence from low- and middle-income countries demonstrated that a decreased
adherence to imatinib treatment was associated with lower 10-year event-free survival [37]. …

… Therapeutic options available for imatinib mesylate (IM) resistance and chronic myeloid
leukemia (CML) stem cells. Various treatment options (indicated in red boxes) have been …

… with chronic myeloid leukemia (CML) has drastically changed following the introduction of
different tyrosine kinase inhibitors (TKIs). In particular, long-term results obtained with imatinib, …

… To better understand how elderly Medicare beneficiaries with CML respond to second-line
nilotinib or dasatinib therapy following initial treatment with imatinib, our group 30 conducted …

… Do we need to increase the sensitivity of detection of BCR-… identify the patients who would
likely remain in treatment-free … chronic myeloid leukemia (CML) were treated with imatinib in …